FDA Expands Bladder Cancer Regimen - Quiz - MDSpire

FDA Expands Bladder Cancer Regimen

KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.

  • By

  • Kathryn Wighton

  • July 10, 2026

  • 2 min

Share

Original Source(s)

FDA Expands Bladder Cancer Regimen

  • by Kathryn Wighton

  • July 10, 2026

Related Content

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Top 10 Evidence-Based Essentials in Internal Medicine

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.